• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off

Card Range To Study



Play button


Play button




Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

64 Cards in this Set

  • Front
  • Back
What causes tuberculosis?
Mycobacterium tuberculosis
Tuberculosis is most commonly found in:
the lungs
Usually, tuberculosis is screened first using a:
skin test
Multi-drug resistant tuberculosis:
resists more than one drug
It is impossible for the result of a Mantoux skin test on an HIV-infected patient to be negative if he or she is infected with tuberculosis.
a) True
b) False
answer: false
The bacteria that cause tuberculosis are transmitted in:
droplet nuclei
Where there is a substantial number of positive tuberculosis skin tests among health care staff, health care personnel should be screened for tuberculosis:
Every six months
What is the easiest source control method to use that reduces air contamination?
Cover patient's mouth with tissues when coughing
When a door or window of an isolation room with negative air pressure is opened, what happens?
Air rushes into the room
Filtering air through a HEPA filter is 100% effective in removing all tuberculosis particles and is the only means necessary to disinfect air.
TB is declining, True or False?
History of Tuberculosis
Worldwide TB kills more people than any other infectious disease 2nd leading killer worldwide
See 1920's-TB leading cause of death in US
1940-1950-Rapid decline r/t drug treatment (INH)
1985-Reemergence steady increase (AIDS)
1993-Global emergency, steady increase in US
1997-Decrease in cases (more screening)
2005-All time low in US @14,097 (CDC)
HIV (immunosuppressed)
Multidrug Resistant Strain (MDR-TB)
Homelessness and crowded living
Decline in Public Health Screening and Education Programs
Increased Global Travel
Dual Infection TB/HIV
14 million worldwide
World Health Organization 3/6/04
Reduce the spread of TB in high HIV areas
Focus Africa=70% of 14m. coinfected live
Increase routine screening of TB in Africa (treat Prophylactic and active)
Provide more collaboration TB/HIV
Department of Public Health
Serious Public Health Problem today
Reportable Communicable Disease (only 78 as of January 2003
Goal of CDC Eradicate from US by 2010
Tuberculosis definition
An infectious disease caused by:
In the US - Mycobacterium Tuberculosis
3 types of Mycobacterial Species
M. Bovis, M. Africanum, and M. Microti
**Gram-positive, acid fast bacillus**
Risk Factors
Close, prolonged contact with active disease
HIV infected
IV drug abusers
Immunocompromised patients (cancer)
High risk environments, prison, shelters, etc.
New immigrants (Africa, Asia, Latin American)
Low socioeconomic groups
M. tuberculosis (bacilli) is inhaled through droplet
Implant in lower sites of the lungs such as the bronchioles or alveoli
Multiply in favorable environments of the lungs: primarily upper lobes
Spread through the lymphatic system to regional lymph nodes
Miliary (spread to all body organs) not usually infectious
Pulmonary transmitted through airborne droplet nuclei-cough, speak, laugh, sneeze
Lungs are always primary site=then spread to other organs via lymphs, bloodstream
Points to remember
Most people exposed resist infection
Clinical evidence occurs in 5-10% of those infected
10% of those exposed become infected
90% of those exposed will develop latent TB capable of reactivation
Estimated that of new infections reported, 60% are reactivation rather than new exposure
Cycle=pneumonia, ulceration, cavitation, and scarring
M. Tuberculosis causes focal inflammation reactions called epitheliod cell granuloma
The organism multiplies slowly and can be killed by ultraviolet light, heat, sunshine
It resists drying, can remain viable for weeks in particles of dried sputum (viable not transmitted)
It is NOT highly contagious, close prolonged frequent contact required.
Latent TB
LTBI is the presence of M. tuberculosis organisms without symptoms or radiographic evidence of TB
As TB disease rates in US decrease, finding and treating LTBI has become a priority.
BCG (Bacille Calmetto-Guerin) vaccine widely used in developing countries
Results in a positive PPD but mean =<10 mm, therefore American Thoracic Society = treat >10 mm
Does not prevent TB but decreases seriousness
Clinical Manifestations
Early: Asymptomatic
Active TB:
anorexia/weight loss
night sweats
low-grade fever
pulmonary: cough, chest pain, hemoptysis and dyspnea
Diagnostic Studies
History and Physical
TST - Tuberculin Skin Test (most common)
CXR-not definitive alone
Bacteriologic Studies
sputum for ACID FAST BACILLUS (smear)
Culture for tubercle bacilli=essential
Collaborative Therapy
American Thoracic Society and CDC recommend TARGETED TUBERCULIN TESTING, not for everyone
Clients with clinical manifestations
Belonging to high or moderate risk groups (health care workers, people who travel)
TB Skin Tests
Multiple Tine Test
small button with several short needles coated with TB antigens
Used in past for TB screening (lots of false negative)
Mantoux Test (PPD)
Called TST (Tuberculin Skin Test)
TB syringe with a measured amount of TB antigen
More accurate
Tuberculin Skin Test (TST)
TST testing is done intradermally by injection of 0.1 mL of PPD (purified protein derivative) tuberculin
Reading in 48-72 hours
Assess for induration
5-15 mm is positive
Administering the TST
Inject 0.1 mL of 5 TU PPD tuberculin solution intradermally on volar surface of lower arm using a 27-gauge needle
Produce a wheal 6 to 10 mm in diameter
Reading the TST
Measure reaction in 48 to 72 hours
Measure induration, NOT erythema
Record reaction in millimeters, not "negative" or "positive"
Ensure trained health care professional measures and interprets the TST
TST-Initial screening test
TST-Positive test indicates presence of TB but not whether active or dormant
Once positive, stay positive, should not keep getting it
Measure in mm the induration (hardness)
Ignore erythema (redness)
TST Interpretation
5-mm induration is interpreted as positive in:
HIV-infected persons
Close contacts to an infectious TB case
Persons with chest radiographs consistent with prior untreated TB
TST Interpretation
5-mm induration is interpreted as positive in (cont.)
Organ transplant recipients(immunosuppressed)
Other immunosuppressed patients (e.g.,those taking the equivalent of >15 mg/d of prednisone for 1 month or those taking TNF-alpha antagonists)
TST Interpretation
10-mm induration is interpreted as positive in:
Recent immigrants (last 5 years)
Injection drug users
Healthcare workers
Residents of long-term care/prisons (close contact)
TST Interpretation
10-mm induration is interpreted as positive in (cont.)
Persons with clinical conditions that place them at high-risk (Immunosuppressed patients)
Children <4 years; infants, children, and adolescents exposed to adults at high-risk
Workers at a mycobacteriology lab
TST Interpretation
15-mm induration is interpreted as positive in:
Persons with no known risk factors for TB
False Negative
Not uncommon in immunosuppressed or elderly >65 years
Two step testing done to prevent this (wait 2-3 wks have another test)
A strategy to determine the difference between boosted reactions and reactions in response to infection
Some people with LTBI may have a negative skin test reaction when tested years after infection because of a waning response.
An initial skin test may stimulate (boost) the ability to react to tuberculin.
Positive reactions to subsequent tests may be misinterpreted as new infections rather than "boosted" reactions.
Two step testing
TST positive=positive
TST negative:
Repeat in 1-3 weeks. If positive (booster phenomenon has occurred.) If negative then client is considered negative.
Required by many companies if no evidence of previous TB test in 1 year, for people requiring yearly TB, elderly and immunocompromised
Anergy testing not recommended by CDC since 1997 (give candida, mumps if positive person is capable of mounting an immune response)
QuantiFERON-TB Gold Blood Test
(instead of TST)
Whole blood used, incubated for 16-24 hrs
The QFT measures the patient's immune reactivity to Mycobacterium tuberculosis
This test was approved by the U.S. Food and Drug Administration (FDA) in 2001.
Will be used more in the future
What are the advantages?
Only requires a single patient visit.
Assesses responses to multiple antigens simultaneously.
Does not cause the booster phenomenon, which can happen with repeat tuberculin skin tests (TST)
Is less subject to reader bias and error when compared to the TST.
What are the disadvantages?
Blood samples must be processed within 12 hours after collection
Currently, there is limited laboratory and clinical experience with the QFT.
The ability of the QFT in predicting a patient's risk of progression to TB disease has not been evaluated.
As with the TST, additional tests are needed to exclude TB disease and confirm diagnosis of LTBI.
Sputum Specimen
Culture & Sensitivity (gold standard for diagnosis)
2-8 weeks for results
Necessary for definitive diagnosis and to determine drug resistance
Sputum Smear
Acid fast bacilli (Start treatment)
Nucleic Acid Amplification (NAA) Rapid test (hrs) - does not replace smear, C&S but adds to clinical picture
Health Care Workers - Protection when obtaining cultures
High Efficiency Particulate Air (HEPA) Filter Mask only mask you can wear taking care of TB patient
Room with reverse air flow and ultraviolet light
Medical Diagonosis
Positive TST
Positive sputum smear for AFB
Positive CXR
Positive biopsy for granulomateous disease
Positive culture of M. Tubercuolosis (tubercle bacilli
(May take >2 weeks)
Management of Latent TB: (Bulk of patients) IF TB IS ENCAPSULATED REGULAR SURGICAL MASK ONLY
RECALL: LTBI is the presence of M. tuberculosis organisms (tubercle bacilli) without symptoms or radiographic evidence of TB disease.
Four recommended treatment regimes
INH qd X 9 months.
1999=Rifampin qd X 2 mos. & pyrazinamide for HIV
INH qd X 12 months. HIV
Rifampin qd X 4 months
Who should be treated for LTBI
IV Drug Users
CXR evidence of previous disease
Clients with high risk medical conditions
Based on:
And size of induration
LTBI vs. Pulmonary TB Disease
Latent TB Infection:
TST or QFT positive
Negative chest radiograph
No symptoms or physical findings suggestive of TB disease
TST or QFT usually positive
Chest radiograph may be abnormal
Symptoms may include one or more of the following: fever, cough, night sweats, weight loss, fatique, hemoptysis, decreased appetite
Respiratory specimens may be smear or culture positive
Active TB
Always use combination therapy
First Line Drug Therapy - RIPE
Rifampin* (longer acting rifampetine)
Isoniazide* (INH)
**Primary agent for Rx (in combo) and prophylaxis (alone=Latent TB)
IM and PO
Highly selective for mycobacteria
May develop resistence
Principle SE=liver toxicity (over 35)
Depletes vitamin B6=peripheral neuropathy
Prolonged Treatment
poor compliance
Drug toxicity
emergence of drug resistance
See handout
Clinical Monitoring
Instruct patient to report signs or symptoms of adverse drug reactions:
anorexia, nausea, vomiting, or abdominal pain in Right Upper Quadrant
Fatigue or Weakness
Dark Urine
Persistent numbness in hands or feet
Clinical Monitoring
Monthly visits should include a brief physical exam and a review of:
rational for treatment
adherence with drug therapy
symptoms of adverse drug reactions
plans to continue treatment
Management of Patient who Missed Doses
Extend or re-start treatment if interruptions were frequent or prolonged enough to preclude complettion
When treatment has been interrupted for more than 2 months, patient should be examined to rule out TB disease
Recommend and arrange for DOT (directly observed therapy) as needed
DOTS (Directly Observed Therapy)
Standard of care for TB
Ensures compliance
Allows for observation of SE
Decrease risk of transmission
Decrease risk of drug resistance
Management & Evaluation
A short hospital stay is possible for teaching and evaluation
1994, the CDC requires isolation for unknown pulmonary problem or TB
Negative pressure room; air is filtered to outside & changed 6-12 X q hour
HIV testing is recommended (pt. consent)
Weekly, monthly & 1 year sputum culture follow-up
Management & Evaluation
Inpatient Care
AFB (acid fast bacillus) Isolation until (-) sputum X 3 days, on meds X 2 weeks and shows clinical response
HEPA air filtration masks by all health care workers
Negative Air Flow Room
Ultraviolet radiation-bactericidal lights
Teaching - cover mouth & nose when coughing, handwashing, compliance, medications (very important)
Permanent Lung Disease and Damage
Possible Lung Resection
Nursing Diagnosis and Planning
Ineffective Breathing Pattern
High Risk for Noncompliance
Activity Intolerance
Ineffective Airway Clearance
Sleep Pattern Disturbance
Ineffective Individual or Family Coping
Diagnostic Phase:
Living conditions
Pulmonary assessment
Treatment Phase:
Knowledge deficits
Willingness and ability to comply with treatment modality
Emotional response to diagnosis
Implementation & Evaluation
Infection Control Measures
Compliance -- Directly Observed Therapy (DOT)
Home Care see handout
R207910-a new class of antimicrobial drugs called diarylquinolines
Faster, better, safer...clinical trials
Still need combination of drugs
Less frequent dosing
With HIV therapies
Meeting the Challenge of TB Prevention
For every patient
Assess TB risk factors for all patients
If risk is present, perform TST or QFT
If TST or QFT is positive, rule out active TB disease
If active TB disease is ruled out, initiate treatment for LTBI
If treatment is initiated, ensure completion